Alkermes PLC (ALKS) Receives Media Impact Score of 0.20
News headlines about Alkermes PLC (NASDAQ:ALKS) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Alkermes PLC earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.1928460325686 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have effected Accern’s rankings:
- Westfield Capital Management Co Lp Modifies Its Stake in Alkermes plc – Ordinary Shares (ALKS) Stock Last Quarter – Highlight Press (highlightpress.com)
- Alkermes plc – Ordinary Shares (NASDAQ:ALKS) Stock Closed Well Below Its 50 Day Average (highlightpress.com)
- IHS Markit Score upgrades Alkermes PLC to 71 out of 100, despite ranking positively in only one IHS Markit category. (finance.yahoo.com)
- $234.90 Million in Sales Expected for Alkermes PLC (NASDAQ:ALKS) This Quarter (americanbankingnews.com)
- See what the IHS Markit Score report has to say about Alkermes PLC. (finance.yahoo.com)
Shares of Alkermes PLC (NASDAQ:ALKS) traded up 0.48% during mid-day trading on Friday, reaching $51.91. 530,353 shares of the company’s stock traded hands. Alkermes PLC has a 52 week low of $41.93 and a 52 week high of $63.40. The firm’s market cap is $7.98 billion. The company’s 50 day moving average is $56.73 and its 200-day moving average is $57.26.
Alkermes PLC (NASDAQ:ALKS) last issued its earnings results on Thursday, July 27th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.02. The company had revenue of $218.80 million during the quarter, compared to analysts’ expectations of $216.54 million. Alkermes PLC had a negative net margin of 24.33% and a negative return on equity of 9.12%. The business’s revenue for the quarter was up 12.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.01) EPS. Equities analysts expect that Alkermes PLC will post ($0.04) earnings per share for the current fiscal year.
A number of equities research analysts have commented on ALKS shares. ValuEngine upgraded Alkermes PLC from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. BidaskClub lowered Alkermes PLC from a “sell” rating to a “strong sell” rating in a research report on Wednesday. Cowen and Company reaffirmed a “buy” rating on shares of Alkermes PLC in a research report on Friday, April 28th. J P Morgan Chase & Co set a $78.00 target price on Alkermes PLC and gave the stock a “buy” rating in a research report on Saturday, July 1st. Finally, Credit Suisse Group set a $70.00 price objective on Alkermes PLC and gave the company a “buy” rating in a research report on Friday, May 19th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the stock. Alkermes PLC has an average rating of “Hold” and a consensus price target of $63.00.
In related news, Director Paul J. Mitchell sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $54.91, for a total transaction of $82,365.00. Following the completion of the transaction, the director now directly owns 9,500 shares in the company, valued at approximately $521,645. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Michael J. Landine sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $57.23, for a total transaction of $572,300.00. Following the transaction, the senior vice president now owns 167,370 shares of the company’s stock, valued at $9,578,585.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 99,500 shares of company stock valued at $5,776,365. 5.34% of the stock is owned by corporate insiders.
Alkermes PLC Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.